Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated

Latest GPR40 Agonist Articles

GPR40 Agonist Archives
Print | Email | Share | Comments (0)

Takeda Ceases Development of Type 2 Drug


Dec 30, 2013

Japanese drug maker Takeda, Asia's largest pharmaceutical company, and a major player in the global diabetes medication market, has ceased development of its type 2 drug, TAK-875 (fasiglifam).

The Osaka-based company said it stopped work on the drug, which its trials showed could be linked to liver damage. Takeda had asked three independent consultant panels to confirm its research before pulling the drug.

"The company has reached the conclusion that, on balance, the benefits of treating patients with fasiglifam do not outweigh the potential risks," Takeda said in a report published in Bloomberg Technology. "Takeda is working with trial investigators and local regulatory authorities to ensure that patients who participated in the fasiglifam trials are transitioned to appropriate therapies."

TAK-875 had already entered Phase 3 studies in Japan, the United States, and Europe when Takeda made the announcement.

The drug is the first in a new class of type 2 drugs called GPR40 (G Protein-Coupled Receptors) agonists. The drug works by countering the deleterious effects of fatty acids on pancreatic beta cells. By stimulating glucose-dependent insulin secretion, it lowers blood glucose levels.

The biggest promise Takeda held out for TAK-875 was that besides lowering A1c's in a statistically significant way, the drug was associated with very little increase in the risk of hypoglycemia.

Takeda was hoping to introduce fasiglifam as an encore to Actos, its mainstay diabetes therapy that generated $3.7 billion in sales in 2011 and accounted for 27 percent of the company's total revenue. In 2012, the drug began facing competition from generic versions, began cutting significantly into its revenue stream.

(Editor's Note: Diabetes Health published a previous referenbce to TAK-875 in its September 17, 2013 report, "Type 2 Drugs in the Pipeline: an Update." The article is available at http://diabeteshealth.com/read/2013/09/17/7992/type-2-drugs-in-the-pipeline-an-update/)


Categories: Fasiglifam, GPR40 Agonist, TAK-875, Takeda, Type 2 Drug



You May Also Be Interested In...


Click Here To View Or Post Comments

Comments 0 comments - Dec 30, 2013

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.